Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Otonomy, Inc. (OTIC)

2.07   -0.01 (-0.48%) 07-02 20:08
Open: 2.1 Pre. Close: 2.08
High: 2.105 Low: 2.02
Volume: 95,542 Market Cap: 118(M)
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.11 - 2.12 2.12 - 2.13
Low: 2 - 2.01 2.01 - 2.02
Close: 2.05 - 2.07 2.07 - 2.09

Technical analysis

as of: 2022-07-01 4:24:14 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.69     One year: 3.15
Support: Support1: 1.95    Support2: 1.74
Resistance: Resistance1: 2.3    Resistance2: 2.69
Pivot: 1.97
Moving Average: MA(5): 2.12     MA(20): 1.97
MA(100): 2.13     MA(250): 1.98
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 59     %D(3): 66.2
RSI: RSI(14): 54.2
52-week: High: 2.58  Low: 1.13
Average Vol(K): 3-Month: 146 (K)  10-Days: 176 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ OTIC ] has closed below upper band by 30.5%. Bollinger Bands are 25.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 30 Jun 2022
Keysight's Participation in O-RAN Global PlugFest Spring 2022 Enables Ecosystem to Speed Open RAN Technology Development and Specifications Maturity - StreetInsider.com

Sat, 25 Jun 2022
Otonomy, Inc. (NASDAQ:OTIC) surges 11%; individual investors who own 32% shares profited along with institutions - Simply Wall St

Fri, 24 Jun 2022
50 medications on Mark Cuban's online pharmacy with the biggest price differences - Becker's Hospital Review

Sun, 19 Jun 2022
Off-label use of otic ciprofloxacin/dexamethasone led to hyperglycemia in infant: Case report - Medical Dialogues

Thu, 09 Jun 2022
O-RAN ALLIANCE Announces Its June 2022 Industry Summit, Progress of Its Global PlugFest Spring 2022 and a New Set of O-RAN Demos - Business Wire

Thu, 09 Jun 2022
Clinical Overview: Ciprofloxacin/Dexamethasone for Acute Otitis Media, Acute Otitis Externa - Pharmacy Times

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 57 (M)
% Held by Insiders 3.904e+007 (%)
% Held by Institutions 2 (%)
Shares Short 536 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.877e+007
EPS Est Next Qtl -0.69
EPS Est This Year -3.24
EPS Est Next Year -2.31
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -39
Return on Assets (ttm) 700
Return on Equity (ttm) -30.8
Qtrly Rev. Growth 125000
Gross Profit (p.s.) -58.48
Sales Per Share -49.41
EBITDA (p.s.) -143275
Qtrly Earnings Growth -0.9
Operating Cash Flow 0 (M)
Levered Free Cash Flow -42 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 3.02

Stock Dividends

Dividend 0
Forward Dividend 505340
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.